Tevogen Bio announces 1-for-50 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

Tevogen Bio Holdings Inc.

Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.
Pre-split shares outstanding: 202,416,556 as of March 3, 2026.
Directors and executive officers beneficially own >70% of common stock.
No fractional shares issued; cash paid in lieu based on closing price day before effective date.
Authorized shares unchanged at 800M; symbol TVGN remains; new CUSIP 88165K200.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Tevogen Bio Holdings Inc.: Effected a 1-for-50 reverse stock split by filing a Certificate of Amendment to the Certificate of Incorporation, effective March 6, 2026 (effective 2026-03-06).

Change: charter amendment
Effective: 2026-03-06

Exact text from the filing

On March 3, 2026, Tevogen Bio Holdings Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of the issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Reverse Stock Split”), to be effective as of March 6, 2026 (the “Effective Date”).

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-008786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.